Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Treace Medical Concepts, Inc. (TMCI) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Treace Medical Concepts, Inc. (TMCI) following potential corporate wrongdoing. The firm is encouraging investors who purchased Treace Medical securities before May 8, 2023, and still hold them, to join the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Average Rating of "Reduce" by Brokerages
Treace Medical Concepts, Inc. (NASDAQ:TMCI) has received an average "Reduce" rating from six brokerages, with two recommending "sell" and four "hold", and a consensus one-year price target of $4.21. Institutional ownership is high at 84.08%, with significant recent activity from hedge funds like AQR Capital Management and Millennium Management. The stock is currently under pressure, trading at its 12-month low of $1.86 and below its 200-day simple moving average.
Treace Medical Concepts (NASDAQ:TMCI) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded Treace Medical Concepts (NASDAQ:TMCI) to a "Sell" rating, contributing to a consensus "Reduce" rating for the stock among analysts. The company's shares opened at a 12-month low of $1.86, with a market capitalization of approximately $118.5 million. Institutional investors hold about 84% of the stock, and the company is known for its Lapiplasty 3D Bunion Correction System.
Treace Medical Concepts to Release Q4 and Full Year 2025 Financial Results
Treace Medical Concepts (TMCI) will release its Q4 and full year 2025 financial results before trading on February 27, 2026, followed by a conference call at 8:00 AM ET. The company is focused on the bunion and midfoot deformity treatment market, which affects approximately 67 million Americans. Treace's Lapiplasty®3D Bunion Correction System and other technologies aim to address these issues and are central to its growth strategy, despite recent analyst downgrades on its price target.
Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026
Treace Medical Concepts, Inc. announced that it will release its fourth-quarter and full-year 2025 financial results on Friday, February 27, 2026, before the market opens. Management will host a conference call at 8:00 AM ET on the same day to discuss these results. Investors can register for the call or access a live and archived webcast on the company's investor relations website to obtain more information.
Treace Medical Concepts to Release Q4 and Full Year 2025 Financial Results
Treace Medical Concepts (TMCI) announced it would release its Q4 and full-year 2025 financial results before trading on February 27, 2026, followed by a conference call at 8:00 am ET. The company, which specializes in bunion and midfoot deformity treatments with its Lapiplasty® 3D Bunion Correction System, faces a significant market demand with approximately 67 million Americans affected by bunions. Despite previous analyst downgrades on its stock, Treace continues its commitment to technological innovation and investor engagement.
Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026
Treace Medical Concepts, Inc. announced that it will release its fourth quarter and full-year 2025 financial results on Friday, February 27, 2026, before market open. Following the release, company management will host a conference call at 8:00 am ET to discuss these results. Investors can register to participate in the call or access a live and archived webcast on the company's investor relations website.
Treace Medical Concepts to Release Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
Treace Medical Concepts, Inc. announced that it will release its fourth quarter and full year 2025 financial results on February 27, 2026, followed by a conference call at 8:00 AM ET. The company, which specializes in surgical treatments for bunions and midfoot deformities with its Lapiplasty® 3D Bunion Correction® System, will discuss its performance and future plans. Investors can register for the conference call and access further details on the company's investor relations website to learn more about its financial updates, patented technologies, and market expansion efforts.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Treace Medical Concepts, Inc. (TMCI) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Treace Medical Concepts, Inc. (NASDAQ:TMCI) for corporate wrongdoing. The firm is encouraging stockholders who purchased TMCI securities before May 8, 2023, and continue to hold them, to connect with their investigation. The law firm operates on a contingency fee basis, meaning investors will not incur costs unless the case is successful.
Stifel Revises Treace Medical Concepts, Inc. (TMCI) Price Target in Sector-Wide Update
Stifel has lowered its price target for Treace Medical Concepts, Inc. (TMCI) to $3 from $5, while maintaining a Hold rating, as part of a broader recalibration within its MedTech coverage. Despite the adjustment, the firm sees a more constructive outlook for the MedTech sector in 2026, especially for large-cap companies. Treace Medical Concepts continues to show steady operational growth, with third-quarter 2025 revenue of $50.2 million, an 11% year-over-year increase, and is focusing on product expansion, surgeon education, and sales force strengthening.
11 High Growth Micro-cap Stocks to Buy
The article identifies Treace Medical Concepts, Inc. (NASDAQ:TMCI) as a high-growth micro-cap stock to consider. Despite a recent price target reduction by Stifel, the company continues to show steady revenue growth and strategic investments to expand its product portfolio and sales organization. Treace Medical Concepts focuses on surgical treatments for bunion and midfoot deformities and is positioned for benefiting from improving MedTech demand.
Treace Medical Concepts (NASDAQ:TMCI) Upgraded at Wall Street Zen
Wall Street Zen upgraded Treace Medical Concepts (NASDAQ:TMCI) from a "sell" to a "hold" rating, though the consensus remains a "Reduce" with an average price target of $4.21. The stock is trading below its 50-day and 200-day moving averages, indicating a continued downtrend despite the company reporting an EPS beat and revenue slightly above estimates. Analysts forecast a negative EPS of -0.92 for the current year.
Institutional owners may consider drastic measures as Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) recent US$29m drop adds to long-term losses
Institutional investors, owning 51% of Treace Medical Concepts, Inc. (TMCI), recently saw their holdings drop by 18%, adding to an 80% loss over the past year. This significant plunge, amounting to US$29 million, could pressure institutions to sell their shares, potentially impacting individual investors. Despite having credibility in the investment community, the company also has 26% insider ownership, including CEO John Treace with an 18% stake, suggesting leadership is invested but highlighting the risks associated with concentrated ownership.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Treace Medical Concepts, Inc. (TMCI) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Treace Medical Concepts, Inc. (NASDAQ:TMCI) for potential corporate wrongdoing. The firm encourages shareholders who purchased TMCI securities before May 8, 2023, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Treace Medical Concepts, Inc. (TMCI) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Treace Medical Concepts, Inc. (TMCI) for corporate wrongdoing. The investigation encourages shareholders who purchased Treace Medical securities before May 8, 2023, and still hold them, to contact the firm to assist in the inquiry. The firm represents investors on a contingency fee basis in securities fraud class actions and shareholder derivative suits.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Average Rating of "Reduce" from Brokerages
Treace Medical Concepts (NASDAQ:TMCI) has received an average "Reduce" rating from six analysts, with two recommending "sell" and four "hold." The consensus one-year price target is $6.57, while the stock currently trades at $2.69. The company remains unprofitable, with analysts forecasting -0.92 EPS for the current fiscal year.
Treace Medical Concepts sees revenue fall in the fourth quarter
Treace Medical Concepts Inc. reported a 9% decline in fourth-quarter revenue to $62.1-$62.5 million, though full-year 2025 revenue increased about 2% to $212.3-$212.7 million. Despite falling stock performance and lowered revenue forecasts in previous years, CEO John Treace expressed confidence in the company's strategy, citing market share gains and increased surgeon usage. The article also covers Redwire's rebranding of Edge Autonomy, an analyst's view on FIS's "clever asset swap", and Landstar System's market outlook.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Treace Medical Concepts, Inc. (TMCI) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Treace Medical Concepts, Inc. (NASDAQ:TMCI) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Treace Medical securities before May 8, 2023, and still hold them, to come forward and assist with the investigation. The representation of investors in securities fraud class actions is on a contingency fee basis.
Treace Medical Concepts, Inc. (TMCI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Treace Medical Concepts, Inc. (TMCI) and its officers/directors. Shareholders who purchased Treace Medical securities before May 8, 2023, and continue to hold them, are encouraged to contact the firm to assist with the investigation. The firm operates on a contingency fee basis, meaning investors will only incur costs if the lawsuit is successful.
Treace Medical Concepts’ preliminary revenue down 9% in Q4 2025
Treace Medical Concepts announced preliminary unaudited revenue results for Q4 and full-year 2025. Fourth-quarter revenue is expected to decrease by approximately 9% at the midpoint compared to 2024, reaching $62.1 million to $62.5 million. Full-year 2025 revenue is projected to increase by about 2% to $212.3 million to $212.7 million, aligning with previous guidance. The company remains focused on expanding its market share and will provide 2026 financial guidance in February.
Treace Medical Concepts, Inc. Provides Preliminary Revenue for the Fourth Quarter of 2025
Treace Medical Concepts, Inc. has announced its preliminary revenue for the fourth quarter of 2025, expecting figures between $62.1 million and $62.5 million. This projection indicates an approximate 9% decrease at the midpoint compared to the same period in 2024. The company specializes in medical technology for the surgical management of bunion and midfoot deformities.
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
Treace Medical Concepts, Inc. announced preliminary, unaudited Q4 and full-year 2025 revenues, showing a slight decrease in Q4 but an annual increase in line with guidance. The company added approximately 202 new active surgeons in 2025, reaching 3,337 total. Despite economic headwinds, Treace anticipates continued positive procedure volume growth and will provide 2026 financial guidance in February.
Bronstein, Gewirtz & Grossman, LLC Encourages Treace Medical Concepts, Inc. (TMCI) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Treace Medical Concepts, Inc. (TMCI) securities prior to May 8, 2023, and still hold them. The investigation focuses on whether Treace Medical and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them to assist in the investigation at no cost.
Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology
Treace Medical Concepts, Inc. announced the successful completion of the first surgical case using its new Lapiplasty® Lightning™ technology. This advanced instrumentation aims to enhance surgical efficiency and precision for 3D bunion correction, streamlining the procedure with features like SpeedPlate® Rapid Compression Fixation. The company plans a limited market release in mid-2026, with full commercialization expected before the end of the year.
Why Investors Shouldn't Be Surprised By Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) Low P/S
Treace Medical Concepts, Inc. (TMCI) has a low price-to-sales (P/S) ratio of 0.9x, which is significantly lower than the industry average for Medical Equipment companies. This low ratio is attributed to the company's recent sluggish revenue growth and negative future revenue forecasts from analysts. Despite strong past growth, anticipated revenue decline explains why the market is not assigning a higher valuation to TMCI.
Why Investors Shouldn't Be Surprised By Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) Low P/S
Treace Medical Concepts, Inc. (NASDAQ:TMCI) has a low price-to-sales (P/S) ratio of 0.9x, which is significantly below the industry average for Medical Equipment companies. This low valuation is attributed to the company's sluggish revenue growth in comparison to its peers, with future revenue forecasts predicting a decline of 2.5% over the next year while the broader industry is expected to expand by 48%. Given these uninspiring growth prospects, the P/S ratio reflects current investor sentiment and is not surprising.
Why Investors Shouldn't Be Surprised By Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) Low P/S
Treace Medical Concepts, Inc. (NASDAQ:TMCI) has a low price-to-sales (P/S) ratio of 0.9x, which is significantly below the industry average for Medical Equipment companies. This low P/S is attributed to the company's sluggish revenue growth in the past and negative revenue growth forecasts for the future, contrasting sharply with the broader industry's expected expansion. Investors are not surprised by the low P/S given these unfavorable revenue trends.
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
Treace Medical Concepts (TMCI) reported a Q1 loss of $0.25 per share, surpassing the Zacks Consensus Estimate of a $0.31 loss. The company's revenues reached $52.57 million, exceeding estimates by 1.05%. Despite this, TMCI shares have seen a 3.2% loss year-to-date, though still outperforming the S&P 500's decline.
Treace Medical Concepts CEO John T. Treace to Present at 44th Annual J.P. Morgan Healthcare Conference
Treace Medical Concepts, Inc. CEO John T. Treace will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 am PT. The company, focused on surgical treatments for bunions and midfoot deformities, will make a live webcast available on its investor relations website. Treace Medical Concepts has innovated the Lapiplasty® 3D Bunion Correction® System and continues to expand its offerings in the medical technology market.
Treace to Present at 44th Annual J.P. Morgan Healthcare Conference
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) announced that CEO John T. Treace will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. A live webcast and replay of the fireside chat will be available on the company's investor relations website. Treace specializes in medical technologies for treating bunions and midfoot deformities.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Rating of "Reduce" from Brokerages
Treace Medical Concepts, Inc. (NASDAQ:TMCI) has received a consensus "Reduce" rating from seven brokerages, with an average 12-month price target of $8.39, significantly higher than its current trading price of $2.42. Analysts cited weak fundamentals, including a negative net margin and projected negative EPS, leading to recent price target cuts from firms like Truist, JPMorgan Chase & Co., and UBS Group. Despite heavy institutional ownership, the stock has been trading down, reflecting continued concerns about its financial performance.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCI
Rosen Law Firm is encouraging investors of Treace Medical Concepts, Inc. (NASDAQ: TMCI) who purchased securities between May 8, 2023, and May 7, 2024, to join a securities class action lawsuit. The firm reminds investors of the June 10, 2025 lead plaintiff deadline and highlights alleged misleading statements by defendants regarding competition, revenue decline, and the need for alternative product offerings. Investors may be entitled to compensation without upfront fees.
Bronstein, Gewirtz & Grossman, LLC Encourages Treace Medical Concepts, Inc. (TMCI) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating Treace Medical Concepts, Inc. (NASDAQ:TMCI) for potential corporate wrongdoing. The investigation encourages shareholders who purchased Treace Medical securities before May 8, 2023, and still hold them, to inquire about their potential claims. The firm represents investors on a contingency fee basis and seeks to recover damages for investors.
L Bronstein, Gewirtz & Grossman, LLC Encourages Treace Medical Concepts, Inc. (TMCI) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Treace Medical Concepts, Inc. (TMCI) securities. The investigation focuses on whether Treace Medical and its officers/directors engaged in corporate wrongdoing, particularly concerning shareholders who purchased securities before May 8, 2023, and continue to hold them. The firm encourages affected investors to contact them for more information, noting that they operate on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Encourages Treace Medical Concepts, Inc. (TMCI) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Treace Medical Concepts, Inc. (TMCI) on behalf of investors who purchased securities before May 8, 2023, and still hold them. The investigation aims to determine if the company and its officers engaged in corporate wrongdoing. Shareholders are encouraged to contact the firm for more information.
Bronstein, Gewirtz & Grossman, LLC Encourages Treace Medical Concepts, Inc. (TMCI) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Treace Medical Concepts, Inc. (NASDAQ:TMCI) securities. The investigation focuses on whether the company and its officers engaged in corporate wrongdoing, particularly for investors who purchased shares before May 8, 2023, and continue to hold them. The firm encourages affected shareholders to contact them for more information and to assist with the investigation.
Class Action Filed Against Treace Medical Concepts, Inc. (TMCI) - June 10, 2025 Deadline to Join - Contact Levi & Korsinsky
A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. (NASDAQ:TMCI) alleging securities fraud between May 8, 2023, and May 7, 2024. Shareholders who suffered losses due to alleged false statements regarding competition impacting demand for their "Lapiplasty" product and subsequent revenue decline are encouraged to contact Levi & Korsinsky LLP by June 10, 2025, to learn about a potential recovery.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Treace Medical Concepts, Inc. (TMCI) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Treace Medical Concepts, Inc. (NASDAQ: TMCI) securities. The investigation focuses on whether Treace Medical's officers and/or directors engaged in corporate wrongdoing. Shareholders who purchased before May 8, 2023, and still hold their shares are encouraged to contact the firm for more information.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Treace Medical Concepts, Inc. (TMCI) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Treace Medical Concepts, Inc. (NASDAQ: TMCI) regarding potential corporate wrongdoing involving its officers and directors. The law firm is seeking to connect with investors who purchased Treace Medical securities before May 8, 2023, and still hold them. Shareholders are encouraged to visit the firm's website or contact them directly to assist in the investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Treace Medical Concepts, Inc. (TMCI) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Treace Medical Concepts, Inc. (NASDAQ:TMCI) who bought shares before May 8, 2023, and continue to hold them. The investigation concerns whether Treace Medical and its officers/directors engaged in corporate wrongdoing. Shareholders are encouraged to connect with the firm to assist the investigation without any cost for their representation.
Treace Medical Secures Up to $175 Million in Debt Financing
Treace Medical Concepts, Inc. has secured a new five-year senior secured debt financing arrangement of up to $175 million with credit funds managed by SLR Capital Partners. This non-dilutive financing includes $60 million in term loans, $65 million of additional term loan availability, and a $50 million revolving credit facility, enhancing the company's financial flexibility and reinforcing its balance sheet to expand its market and strengthen its competitive position in bunion surgery. Proceeds from the new term loan were used to prepay existing debt.
Treace Medical Secures Up To $175 Million In Debt Financing
Treace Medical Concepts Inc. (TMCI) has secured up to $175 million in debt financing, with the proceeds being used to pre-pay an existing $50 million term loan. The new loan has a five-year maturity.
Treace Medical Concepts Announces $175 Million Secured Loan Agreement to Enhance Financial Flexibility and Market Position
Treace Medical Concepts, Inc. secured a five-year, $175 million senior secured loan agreement with SLR Capital Partners to enhance financial flexibility and expand its market presence in bunion surgery. This non-dilutive financing includes initial term loans, additional term loan availability, and a revolving credit facility. The company plans to use the proceeds to prepay existing loans, reinforcing its balance sheet with approximately $165 million in total liquidity and supporting its goal of becoming the standard in bunion surgery.
Treace Medical Secures Up to $175 Million in Debt Financing
Treace Medical Concepts, Inc. has secured a new five-year, $175 million senior secured loan arrangement with credit funds managed by SLR Capital Partners. This financing includes $60 million in term loans, $65 million in additional term loan availability, and a $50 million revolving credit facility, aimed at reinforcing the company's balance sheet and enhancing financial flexibility to support its commercial strategies and market expansion. The new agreement provides 48 months of interest-only payments for the term loan, which can be extended by an additional 12 months, and replaces previous debt obligations.
Truist Securities Trims Price Target on Treace Medical Concepts to $3 From $4, Maintains Hold Rating
Truist Securities has reduced its price target for Treace Medical Concepts (NASDAQ: TMCI) to $3 from $4, while maintaining a Hold rating on the stock. This adjustment comes amidst other recent analyst actions, including Truist's earlier cut to $4 from $7 and JPMorgan's downgrade to Underweight.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Treace Medical Concepts, Inc. (TMCI) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Treace Medical Concepts, Inc. (NASDAQ:TMCI) and its officers/directors. The firm is encouraging shareholders who purchased Treace Medical securities before May 8, 2023, and still hold them, to come forward and assist in the investigation. This investigation aims to determine if claims can be made on behalf of these investors.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCI
Rosen Law Firm reminds investors of Treace Medical Concepts, Inc. (NASDAQ: TMCI) who purchased securities between May 8, 2023, and May 7, 2024, that the lead plaintiff deadline for a securities class action is June 10, 2025. The lawsuit alleges that Treace Medical made misleading statements regarding demand for its Lapiplasty product, its declining revenue, and the need for an alternative product due to competition, resulting in investor damages. Investors are encouraged to secure counsel.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Treace Medical Concepts, Inc. (TMCI) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Treace Medical Concepts, Inc. (TMCI) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased TMCI securities before May 8, 2023, and still hold them, to come forward and assist in the investigation. The investigation aims to uncover any misconduct by Treace Medical and its officers or directors.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Treace Medical Concepts, Inc. (TMCI) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Treace Medical Concepts, Inc. (TMCI) for potential corporate wrongdoing. The firm is encouraging shareholders who purchased TMCI securities before May 8, 2023, and still hold them, to come forward and assist in the investigation. The investigation aims to determine if Treace Medical and its officers/directors engaged in illicit practices.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Treace Medical Concepts, Inc. (TMCI) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Treace Medical Concepts, Inc. (NASDAQ:TMCI) regarding potential corporate wrongdoing. The firm is encouraging shareholders who purchased Treace Medical securities before May 8, 2023, and continue to hold them, to learn more about the ongoing investigation. Investors can assist the investigation by visiting the firm's website or contacting their client relations managers, with no cost to them for participation.
